Immune checkpoint blockade was an important strategy for glioma treatment; several regular checkpoint molecules were included in our study, and it indicated that except for PVRIG, CD200, and VTCN1, immune checkpoints were substantially higher in the high-risk group (Figure 6(d)). The gene discussed is VTCN1; the disease is glioma.